A 26-week, randomized, placebo- and active-comparator-controlled, parallel-group, double-blind, 2-part study to assess the safety and efficacy of etoricoxib 30 mg versus celecoxib 200 mg in patients with osteoarthritis (Study 2)

Trial Profile

A 26-week, randomized, placebo- and active-comparator-controlled, parallel-group, double-blind, 2-part study to assess the safety and efficacy of etoricoxib 30 mg versus celecoxib 200 mg in patients with osteoarthritis (Study 2)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Etoricoxib (Primary) ; Celecoxib
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top